Identifying the Course of Dementia Using Medical Records: the CoMed Study
NCT ID: NCT03817138
Last Updated: 2020-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
258 participants
OBSERVATIONAL
2019-07-09
2020-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sharing the Outcome of a Memory Assessment
NCT04935060
Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries
NCT02549872
Natural History and Patient Journey in Dementia: a Nationwide Linked Electronic Health Records Study of 5.6 Million Individuals.
NCT04321486
Promoting Activity, Independence and Stability in Early Dementia and Mild Cognitive Impairment
NCT04065854
Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
NCT03134963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One potential major resource for studying these issues in primary care are Electronic Health Record (EHR) databases which contain routinely recorded information from consultations with a GP and other healthcare professional such as illnesses and treatment provided. They are a useful resource for studying how illnesses progress after diagnosis in primary care and have been used to investigate disease course, outcomes and patient care in a wide spectrum of diseases. However, to date, they have not been used to research the course of dementia after diagnosis. Existing evidence has established important dementia outcomes (e.g. nursing home placement, hospital admissions, mortality) are recorded within EHR and a systematic review that has recently been performed suggests other illnesses and symptoms (e.g. cognitive status, neuropsychiatric symptoms), may be recorded within primary care EHR and could serve as markers of disease progression.
To address this research gap the research will identify possible markers of disease progression from routinely collected in primary care medical records and compare them against assessments of disease progression from specialist dementia service medical records. The study will enable healthcare professionals to use routinely recorded information in primary care, without the need for intensive assessments, to identify individuals with dementia who are at risk of a faster disease progression. This will drive the future development and delivery of treatment to the individual patient with dementia based on their likely future course.
The CoMed study is a retrospective cohort design linking dementia service and primary care medical records. Potential participants' only involvement will be a request for consent to access and link these medical records.
Participants will be recruited from a secondary care dementia service.
All patients who have a confirmed diagnosis of dementia in the dementia service medical records and who have been assessed by the dementia service at more than one-time point at least 12 months apart will be identified (a 12-month gap is the minimum necessary to determine disease progression). The first 1000 eligible patients will be initially identified (expected number required to obtain sample size required of 400 patients), however, further searches can be carried out if the expected response and recruitment rate is not met. The list of patients to be invited will be screened by the patient's clinical care team in the participating dementia service to exclude those who it would be inappropriate to contact as it may cause undue distress or harm.
Eligible patients who have been seen by the dementia service within the previous 12 months will be identified by the dementia service clinical care team. These eligible patients will be sent by post the study information pack containing: an invitation letter, patient and personal consultee information leaflets, patient consent and personal consultee declaration forms, and a stamped addressed return envelope. If there is no reply to the initial invitation, then a reminder invitation and study information pack will be sent after a minimum of 2 weeks. A poster about the study will be displayed in the dementia service clinical areas and waiting areas, and a copy of the poster in leaflet form will be available for patients to take away and read if they wish.
A review of the response and recruitment rate will be undertaken at regular intervals to assess whether more patients need to be identified (based on a 40% recruitment rate). If the required number of patients is not achieved additional recruitment strategy will be initiated. An additional search of the dementia service medical records to identify further eligible patients and study packs will be posted out.
For those who are willing to take part in the study written informed consent will be obtained from patients with dementia (or personal consultee's advice for those not able to give consent) to access their dementia service medical records and their primary care medical records and for these to be linked and used for research purposes.
In those consenting to take part in the study, patient data will be retrieved from the dementia service records including detailed clinical assessments of cognitive status, behavioural and function assessments, and the time points of these assessments. The patient's primary care medical records will be requested from their GP practice. Details on how to electronically download the requested medical records and securely transfer them via the secure NHS email system will be included with the letter to GP practices.
Confidentiality and anonymity will be maintained for all participants. All information collected regarding participants will be kept confidential. Participants will be free to withdraw from the study and to request their medical records are not used up to a period of one month from the date consent is given. After this point, pseudoanonymised data will be used and it will not be possible to identify patients to remove their medical records from the analysis dataset. The presence or absence of potential markers of progression recorded in patients' primary care records will then be compared to change in scores from standard clinic assessments recorded at the specialist dementia clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposures: Markers of disease progression
From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of dementia in the dementia service medical records
* Assessment by the dementia service on two or more occasions at least 12 months apart (timescale required to determine disease progression)
* Recorded appointment with the dementia service in last 12 months
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Dunhill Medical Trust
OTHER
Midlands Partnership NHS Foundation Trust
UNKNOWN
University of Sheffield
OTHER
University of Warwick
OTHER
University College, London
OTHER
Newcastle University
OTHER
Keele University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kelvin Jordan, PhD
Role: STUDY_DIRECTOR
Keele University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Midlands Partnership NHS Foundation Trust
Stafford, Staffordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG-0280-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.